Dashboard
1
Poor Management Efficiency with a low ROCE of 7.29%
- The company has been able to generate a Return on Capital Employed (avg) of 7.29% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -7.38% and Operating profit at -183.88% over the last 5 years
3
The company has declared negative results for the last 4 consecutive quarters
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,520 Million (Small Cap)
NA (Loss Making)
NA
0.67%
-0.46
-1.89%
1.17
Revenue and Profits:
Net Sales:
104 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.76%
0%
31.76%
6 Months
99.28%
0%
99.28%
1 Year
90.5%
0%
90.5%
2 Years
62.86%
0%
62.86%
3 Years
18.3%
0%
18.3%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Chengda Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.38%
EBIT Growth (5y)
-183.88%
EBIT to Interest (avg)
32.47
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.16
Tax Ratio
6.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.29%
ROE (avg)
3.25%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-22.90
EV to EBITDA
137.73
EV to Capital Employed
1.32
EV to Sales
4.38
PEG Ratio
NA
Dividend Yield
0.67%
ROCE (Latest)
-5.74%
ROE (Latest)
-1.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
104.10
61.40
69.54%
Operating Profit (PBDIT) excl Other Income
29.60
2.80
957.14%
Interest
0.60
0.00
Exceptional Items
2.50
3.70
-32.43%
Consolidate Net Profit
14.30
6.50
120.00%
Operating Profit Margin (Excl OI)
74.30%
-181.60%
25.59%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 69.54% vs -3.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 120.00% vs -33.67% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
328.80
410.70
-19.94%
Operating Profit (PBDIT) excl Other Income
-4.60
103.10
-104.46%
Interest
0.40
0.10
300.00%
Exceptional Items
1.60
0.00
Consolidate Net Profit
-27.60
91.10
-130.30%
Operating Profit Margin (Excl OI)
-200.70%
132.40%
-33.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.94% vs 0.83% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -130.30% vs -14.46% in Dec 2023
About Chengda Pharmaceuticals Co., Ltd. 
Chengda Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






